January 2 and 8, 2025 — VJTBio, a pioneer in animal innovative drugs, and WuXi Biologics (2269.HK), a global leading CRDMO (Contract Research, Development and Manufacturing Organization) service company, held grand signing ceremonies in Beijing and Shanghai respectively. They jointly announced a global strategic cooperation to jointly promote the accelerated development of the global animal health industry.
VJTBio, as a global leader in animal innovative drugs, has a pipeline of innovative drugs covering animal reproduction, disease prevention and control, and pet disease treatment. Many of its products are world - first, with significant industry - benchmarking significance. According to the cooperation agreement, WuXi Biologics, as the preferred partner of VJTBio, will leverage its leading integrated technology platform PawBioTM, efficient cost management, and flexible global production network to empower the research and development and production of VJTBio 's global animal innovative drugs and jointly expand the global market for animal innovative drugs.
Dr. Luo Haoshu, Chairman of VJTBio, said: "Our strategic cooperation with WuXi Biologics is not only a strong alliance between two companies, but also another important milestone for Chinese biopharmaceutical products to enter the global market in the field of animal health. WuXi Biologics enjoys a high reputation in the global biopharmaceutical field, and its advanced technology platform and rich international cooperation experience will provide strong support for our innovative drug research and development. We believe that through the complementary advantages of both parties, we can accelerate the development process of new drugs and bring more innovative results to the world."
Dr. Chen Zhisheng, CEO of WuXi Biologics, said: "We are very pleased to cooperate with VJTBio to jointly promote the vigorous development of the global animal health innovation drug field. WuXi Biologics has launched a one - stop solution for animal health biopharmaceuticals, PawBioTM. With the project experience accumulated in the human medicine field for many years, the leading technology platform and excellent service quality, we will help global partners accelerate the process of animal biopharmaceuticals coming to market and inject innovative momentum into the animal health field."
About VJTBio
VJTBio focuses on the global animal innovative drug market, which is worth hundreds of billions of yuan. It is a biopharmaceutical company that integrates the research and development, production, and sales of animal health products. It is a global leader in animal innovative drugs. We are committed to the research and development of animal recombinant protein antibody drugs and mRNA vaccines. Our pipeline includes more than ten innovative drug varieties, basically national Class I new veterinary drugs. These varieties cover three major fields: animal reproduction, disease prevention and control, and pet disease treatment. Among them, many varieties have global PCT patents and are world - first. VJTBio has always adhered to the mission of "caring for animals and being concerned about humanity" and practiced the principle of "revering life and making medicine devoutly". We focus highly on the research and development of animal innovative drugs and are committed to providing innovative solutions for global animal health. Animal health is not only the key to sustainable agricultural development, but also an important part of human health. Through years of efforts, the company has a highly professional biopharmaceutical team and has a comprehensive competitive advantage in the complete industrial chain. All links from R & D to pilot production, registration application to clinical trials, production base to market sales have been fully connected. The Beijing R & D center of VJTBio has internationally leading hardware facilities and technology platforms for the development of protein antibody drugs and mRNA vaccines. The Zhejiang production base is the first domestic animal protein antibody drug veterinary GMP production line based on CHO expression system. VJTBio contact: vjtpublic@vjtbio.com, for more information, please visit: www.vjtbio.com
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a global leading CRDMO company. The company provides all - round end - to - end services through an open and integrated biopharmaceutical capability and technology empowerment platform, helping partners discover, develop and produce biopharmaceuticals, realizing the whole process from concept to commercial production, accelerating the global biopharmaceutical R & D process, reducing R & D costs, and benefiting patients. WuXi Biologics has more than 12,000 employees in China, the United States, Ireland, Germany and Singapore. Through WuXi Biologics' professional service team, as well as advanced technology and in - depth insights, the company provides efficient and cost - effective biopharmaceutical solutions for customers. As of the end of June 2024, WuXi Biologics has helped customers with a total of 742 integrated projects in R & D and production, including 16 commercial production projects (excluding COVID - 19 projects and inactive projects). WuXi Biologics regards ESG (Environmental, Social and Governance) as an important part of business development and corporate spirit, and is committed to becoming a leader in ESG in the global biopharmaceutical CRDMO field, such as leading the industry development by applying more green and environmentally friendly new - generation biopharmaceutical technologies and energy. The company has established an ESG Committee led by the CEO to fully implement the ESG strategy and practice the commitment to sustainable development. WuXi Biologics business inquiry: info@wuxibiologics.com, WuXi Biologics media relations: PR@wuxibiologics.com, for more information, please visit: www.wuxibiologics.com